These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23118780)

  • 1. Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease.
    Pavlidis P; Romanidou O; Roggenbuck D; Mytilinaiou MG; Al-Sulttan F; Liaskos C; Smyk DS; Koutsoumpas AL; Rigopoulou EI; Conrad K; Forbes A; Bogdanos DP
    Clin Dev Immunol; 2012; 2012():640835. PubMed ID: 23118780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
    Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
    Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
    Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
    BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
    Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
    Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
    Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
    Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
    Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
    J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
    Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
    Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein 2 antibodies in Crohn's disease.
    Roggenbuck D; Reinhold D; Werner L; Schierack P; Bogdanos DP; Conrad K
    Adv Clin Chem; 2013; 60():187-208. PubMed ID: 23724745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
    Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
    Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
    Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
    Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease-specific pancreatic autoantibodies are specifically present in ruminants with paratuberculosis: implications for the pathogenesis of the human disease.
    Liaskos C; Spyrou V; Roggenbuck D; Athanasiou LV; Orfanidou T; Mavropoulos A; Reinhold D; Rigopoulou EI; Amiridis GS; Billinis C; Bogdanos DP
    Autoimmunity; 2013 Sep; 46(6):388-94. PubMed ID: 23638886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
    Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
    Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
    Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
    J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crohn's disease specific pancreatic antibodies: clinical and pathophysiological challenges.
    Roggenbuck D; Reinhold D; Schierack P; Bogdanos DP; Conrad K; Laass MW
    Clin Chem Lab Med; 2014 Apr; 52(4):483-94. PubMed ID: 24231127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory Bowel Disease-associated GP2 Autoantibodies Inhibit Mucosal Immune Response to Adherent-invasive Bacteria.
    Derer S; Brethack AK; Pietsch C; Jendrek ST; Nitzsche T; Bokemeyer A; Hov JR; Schäffler H; Bettenworth D; Grassl GA; Sina C
    Inflamm Bowel Dis; 2020 Nov; 26(12):1856-1868. PubMed ID: 32304568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease.
    Roggenbuck D; Vermeire S; Hoffman I; Reinhold D; Schierack P; Goihl A; von Arnim U; De Hertogh G; Polymeros D; Bogdanos DP; Bossuyt X
    Clin Chem Lab Med; 2015 Aug; 53(9):1349-57. PubMed ID: 25411995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
    Pavlidis P; Shums Z; Koutsoumpas AL; Milo J; Papp M; Umemura T; Lakatos PL; Smyk DS; Bogdanos DP; Forbes A; Norman GL
    Clin Chim Acta; 2015 Feb; 441():176-81. PubMed ID: 25512163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies.
    Bogdanos DP; Rigopoulou EI; Smyk DS; Roggenbuck D; Reinhold D; Forbes A; Laass MW; Conrad K
    Autoimmun Rev; 2011 Dec; 11(2):143-8. PubMed ID: 21983481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.
    Somma V; Ababneh H; Ababneh A; Gatti S; Romagnoli V; Bendia E; Conrad K; Bogdanos DP; Roggenbuck D; Ciarrocchi G
    Gastroenterol Res Pract; 2013; 2013():683824. PubMed ID: 23762038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.